Nelfinavir markedly increases
terfenadine levels, which is expected to increase the risk of QT prolongation and torsade de pointes arrhythmias. Other
protease inhibitors are predicted to interact similarly with both
terfenadine and
astemizole.
Concurrent use is contraindicated.